

Holtz Children and Women Hospital

ANTIMICROBIAL SUSCEPTIBILITY REPORT: January - December (2016)

Data include 1st isolate per patient

	Percent susceptible (*)												
GRAM-NEGATIVE ISOLATES	No.	TZP	CAZ	CRO	FEP**)	ATM	MER	AN	GM	TOB	LVX	TET	SXT
<i>Escherichia coli</i> (***)	282	91	88	84	90	nd	100	99	81	83	81	57	56
<i>Citrobacter freundii</i>	9	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
<i>Citrobacter koseri</i>	2	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
<i>Klebsiella pneumoniae</i>	105	85	88	87	92	nd	99	98	92	90	105	80	81
<i>Enterobacter aerogenes</i>	27	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
<i>Enterobacter cloacae</i> complex	70	91	81	81	93	83	100	100	97	97	98	94	91
<i>Serratia marcescens</i>	27	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
<i>Proteus mirabilis</i>	40	98	98	95	98	nd	98	100	95	95	95	/	90
<i>Morganella morganii</i>	7	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
<i>Pseudomonas aeruginosa</i>	100	91	86	ns	84	nd	98	94	88	91	83	ns	ns
<i>Acinetobacter baumannii</i>	22	ns	ns	/	/	/	ns	/	ns	ns	ns	ns	/
<i>Stenotrophomonas maltophilia</i>	27	/	/	/	/	/	/	/	/	/	ns	/	ns

AMP AMPICILLIN
AMS AMPICILLIN/SULE
AN AMIKACIN
ATM AZTREONAM
CAZ CEFTAZIDIME
CLN CLINDAMYCIN
CRO CEFTRIAXONE
CTX CEFOTAXIME
CZ CEFAZOLIN
ERT ERTAPENEM
FEP CEFEPIME
FOX CEFOXITIN
GM GENTAMICIN
LVX LEVOFLOXACIN
LZD LINEZOLID
MER MEROPENEM
PEN PENICILLIN
RIF RIFAMPIN
OX OXACILLIN
SXT TRIMETH/SULFA
TET TETRACYCLINE
TOB TOBRAMYCIN
TZP PIPERACILLIN/TA
VA VANCOMYCIN

(*) Clinical Laboratory Standards Institute (CLSI) M100-S26, 2016 breakpoints for antibiotic susceptibility

(**) *Enterobacteriaceae*, two cefepime has two dose-dependent susceptibility breakpoints: susceptible at 1g q12 and at (2g q8)

(***) 183 of urinary *Escherichia coli* isolates 90% (n = 202) susceptible to nitrofurantoin

(/) slash indicates that the drug is clinically ineffective or <20% susceptible (Sanford Guide to Antimicrobial Therapy, 2015)

(nd) no antibiotic susceptibility data available

(ns) statistical significance uncertain due to insufficient number of isolates

	Percent susceptible (*)												
GRAM-POSITIVE ISOLATES	No.	AMP	PEN	OX	CTX	CLN	GM	LVX	RIF	TET	LZD	VA	SXT
<i>Enterococcus faecalis</i>	63	95	/	/	/	/	/	/	/	/	100	97	/
<i>Enterococcus faecium</i>	3	ns	/	/	/	/	/	/	/	ns	ns	ns	/
<i>Staph aureus</i> MRSA ^a	100	/	ns	0	nd	83	99	/	100	87	nd	100	97
<i>Staph aureus</i> MSSA ^a	118	/	ns	100	nd	70	98	/	99	91	nd	100	97
<i>Staphylococcus epidermidis</i> ^a	76	/	nd	26	/	41	59	/	99	87	nd	100	68
Coagulase Neg. Staph (exc <i>S. epidermidis</i>)	63	/	nd	61	/	65	90	/	99	79	nd	100	68
<i>Streptococcus agalactiae</i>	13	ns	ns	/	ns	ns	/	ns	/	/	/	ns	/
<i>Streptococcus pneumoniae</i>	8	/	ns	/	nd	ns	/	ns	/	/	/	ns	/

(a) *S. aureus* and coagulase-negative staph (CNS) resistant to oxacillin are resistant to penicillins, cephalosporins and carbapenems

Overall MRSA = 46 % of all *Staphylococcus aureus* isolates

3ACTAM

PIPERACILLIN/TAZO